Bouncing back from a shocking CRL, Athenex shares soar with buyout of natural killer T cell player

Nicole DeFeudis

Editor

Several weeks after Athenex was hit with a surprise CRL for its oral chemotherapy candidate — and a class-action lawsuit to boot — the company’s stock …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bouncing back from a shocking CRL, Athenex shares soar with buyout of natural killer T cell player

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bounc­ing back from a shock­ing CRL, Athenex shares soar with buy­out of nat­ur­al killer T cell play­er

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bouncing back from a shocking CRL, Athenex shares soar with buyout of natural killer T cell player